Skip to content

Effects of different doses of Esketamine and dexmedetomidine on emergence agitation in Pediatric Tonsillectomy and Adenoidectomy

Effects of different doses of Esketamine and dexmedetomidine on emergence agitation in Pediatric Tonsillectomy and Adenoidectomy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300067522
Enrollment
Unknown
Registered
2023-01-10
Start date
2023-02-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emergence agitation in Pediatric Tonsillectomy and Adenoidectomy

Interventions

Dexmedetomidine(group D):Dexmedetomidine was infused by 0.3µg/kg in 10min
Dexmedetomidine and esketamine 0.1mg/kg(group DE1):Dexmedetomidine was infused by 0.3µg/kg in 10min and esketamin 0.1mg/kg iv
Dexmedetomidine and esketamine 0.1mg/kg(group DE2):Dexmedetomidine was infused by 0.3µg/kg in 10min and esketamin 0.2mg/kg iv

Sponsors

The First Affiliated Hospital of Fujian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 7 Years

Inclusion criteria

Inclusion criteria: 1. ASA I-II; 2. 3-7 years old; 3. Selective tonsillectomy and adenoidectomy operation under general anesthesia in children

Exclusion criteria

Exclusion criteria: 1. The guardian of the child refuses the test; 2. Suffering from serious chronic diseases such as heart, liver and kidney; 3. There were obvious abnormalities in preoperative examination (electrocardiogram, plain chest film); 4. Patients with obstructive sleep apnea syndrome (OSAS), asthma, upper airway abnormalities, and a history of respiratory infection in the last 2 weeks; 5. Developmental retardation or BMI > 30kg/m2

Design outcomes

Primary

MeasureTime frame
the incidence of emergence agitation in Pediatric Tonsillectomy and Adenoidectomy;

Secondary

MeasureTime frame
The best drug combination with fewer adverse reactions;

Countries

China

Contacts

Public ContactKai Zeng

The First Affiliated Hospital of Fujian Medical University

Zengkai6822@163.com13055291712

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026